{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"TRM will be summarized descriptively (death within 100 days without relapse following ASCT).","groups":[{"description":"Patients will receive 200 mg/m\\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).\n\nMelphalan HCl for injection (propylene glycol free): During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.","id":"OG000","title":"Melphalan HCl for Injection (Propylene Glycol Free)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"100 days","title":"Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)","type":"SECONDARY","unitOfMeasure":"Participants"}